|
Market Cap (1-Jul) $2,324,063,488 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (19-Jun) 79,324,475 (6.21%) (26th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.13 |
A news article has been posted about Mesoblast on the AFR. The article was published around , on 15 December 2020 at 4:43pm.
Shares in Mesoblast have been smashed at the opening of trade on the ASX on Tuesday, tumbling more than 10 per cent after the stem cell therapy group missed the primary endpoint in a trial of its heart treatmentRevascor. Before the market opened, Mesoblast ...
Read ArticleMSB was $4.54 at the close of trade on 14 December 2020
| Recent Articles about ASX:MSB | |
|---|---|
| 31-Dec | Zip Co, Mesoblast among ASX's best performers in 2024
canberratimes.com.au |
| 31-Dec | Why DroneShield, Invictus Energy, Mesoblast, Weebit Nano shares are rising today
msn.com |
| 31-Dec | Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
seekingalpha.com |
| 31-Dec | Remestemcel-L by Mesoblast for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
pharmaceutical-technology.com |
| 27-Dec | Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today
msn.com |
| 27-Dec | Mesoblast Sees Major Change in Substantial Holding
markets.businessinsider.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group
etfdailynews.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Shares Gap Up – Here’s Why
etfdailynews.com |
| 24-Dec | Mesoblast scores first US nod for mesenchymal stromal cell therapy
bioworld.com |
| 23-Dec | Mesoblast Director Increases Share Holdings Significantly
nasdaq.com |
| Tracked |
Find all articles about Mesoblast, including others on the AFR, on the media page.
You must be logged in to post a reply.
Mesoblast 